Brito P, et al. - Researchers conducted the study for investigating the role of serum levels of pro-inflammatory factors in the identification of persistent diabetic macular oedema (DME) cases with the limited anatomic response to anti-VEGF, as well as analyzing possible predictive connections between serum factors and intravitreal treatment profiles. DME cases have been treated with monthly bevacizumab. In total, 58 cases have been involved receiving a mean of 7.23 ± 1.55 IVI in 12 months, resulting in a significant improvement of visual acuity and central foveal thickness. According to findings, serum markers of microvascular damage (high-sensitivity C-reactive protein, homocysteine and creatinine) were linked to a higher frequency of IVI due to persistent DME, indicating a role for such biomarkers in the identification of limited responders to anti-VEGF monotherapy.